吉西他宾和奥沙利铂联合化疗治疗耐药性卵巢上皮癌的临床分析  

Clinical analysis of the combination of Gemcitabin and Oxaliplatin in the treatment of drug-resistant epithelial ovarian cancer

作　　者：方晏平 吴玉萍 

机构地区：[1]武汉市江夏区第一人民医院妇产科,湖北武汉430200

出　　处：《中国医药导报》2012年第4期65-66,共2页China Medical Herald

摘　　要：目的研究吉西他宾和奥沙利铂联合治疗耐药性卵巢上皮癌的有效性和安全性。方法将我院收治的耐药性卵巢上皮癌患者21例纳入本研究,所有患者给予吉西他宾1 000 mg/m2,奥沙利铂100 mg/m2,并对其疗效及副作用进行回顾性分析。结果 21例患者中,完全缓解10例(47.6%),部分缓解6例(28.6%),病情稳定l例(4.8%),病情进展4例(19.0%),有效率达76.2%。化疗后无肿瘤进展时间的中位数为11.3个月,总生存时间的中位数为30.7个月。化疗过程中,血液学副作用(Ⅲ～Ⅳ度)的发生率为31.3%,其他副作用包括浅表静脉炎(28.8%)、周围神经毒性反应(37.5%)、过敏和皮疹(13.8%)。结论吉西他宾和奥沙利铂联合用于耐药性卵巢上皮性癌患者的挽救性化疗,其副作用可耐受,疗效较好,是一种有效的选择。Objective To study the efficacy and security of the combination of Gemcitabin and Oxaliplatin in drug-resistant epithelial ovarian cancer.Methods 21 patients with drug-resistant epithelial ovarian cancer in our hospital were enrolled.All patients were given Gemcitabin 1 000 mg/m2 and Oxaliplatin 100 mg/m2,the efficacy and side effects were analyzed retrospectively.Results There were 10 cases with complete response（47.6%）,6 cases with partial response（28.6%）,1 case with stable disease（4.8%）,and 4 cases with disease progression（19.0%） among 21 cases.The response rate was 76.2%.The median progression-free and overall survival time was 11.3 months and 30.7 months after treatment.During tveatment,grade Ⅲ-Ⅳ myelosuppression rate was 31.3%.Other side effects included superficial phlebitis（28.8%）,peripheral nerve toxicity（37.5%）,allergy and rash（13.8%）.Conclusion The combination of Gemcitabin and Oxaliplatin is an effective choice in the treatment of drug-resistant ovarian carcinoma with high activity and acceptable toxicity.

关 键 词：卵巢上皮癌 吉西他宾 奥沙利铂 联合化疗方案 

分 类 号：R737.31[医药卫生—肿瘤]